Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Gazyva (obinutuzumab) for the Treatment of Chronic Lymphocytic Leukaemia (CLL)

Drug Name (Brand/Generic)

Gazyva / obinutuzumab / GA101

Company / Licensee

Roche / Biogen Idec

Therapy Class

Monoclonal antibody

Current Indication

Chronic Lymphocytic Leukaemia (CLL), follicular lymphoma

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top